echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first immunotumor treatment drug is on the market, and Bristol Meishi Guibao has made rapid progress as the "leader"

    The first immunotumor treatment drug is on the market, and Bristol Meishi Guibao has made rapid progress as the "leader"

    • Last Update: 2018-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The slogan "time is money, efficiency is life" was born in Shenzhen, China in 1982, which is known as the beginning sign of China's market economy Now it is becoming the working principle of more and more multinational pharmaceutical enterprises in China On August 10, BMS announced that opdivo, the first PD-1 inhibitor approved for marketing in China, will be officially launched in China in the third quarter of this year for the treatment of epidermal growth factor receptor (EGFR) gene mutation after it was approved by the State Drug Administration on June 15 Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have negative and anaplastic lymphoma kinase (ALK) negative and who have previously received chemotherapy with platinum containing regimen and who have progressed or are intolerable have become the only approved PD-1 inhibitor in the field of lung cancer in China From $0 to $5.8 billion, according to l.e.k., a consultancy, the global tumor immunotherapy market will increase from $7 billion in 2016 to $48 billion in 2022, a sevenfold increase in six years By then, it could account for more than a quarter of the $180 billion cancer treatment market As the world's second largest pharmaceutical market after the United States, the prospect of immunotherapy in China is also exciting According to the prediction of frost and Sullivan, the consulting agency, in the next four years from 2018, China's immune tumor market will soar from almost zero to $5.8 billion, and even to $12.1 billion by 2025, which can hardly be described as explosive growth And the approval of oedival's listing will undoubtedly be the first flame of this outbreak On June 15 this year, the State Drug Administration officially approved the first domestic application for listing of PD-1 inhibitors, which ushered in the era of immunotherapy Professor Wu Yilong, life-long director of Guangdong People's Hospital and chairman of the China chest cancer research cooperation group, said, "at present, the overall effective rate of immunotherapy is about 20% Although there is no targeted treatment with high effective rate and relatively slow effect, once it works, the therapeutic effect lasts for a long time, and the side effects of immunotherapy are smaller than chemotherapy." Li Zhizhong, a doctor of cancer biology at Duke University and a famous cancer science writer, explained that immunotherapy has a unique "long tail effect of survival" Patients with effective immunotherapy have a great chance of high-quality long-term survival, and those who have been sentenced to death for advanced cancer are often referred to as "super survivors" Among the patients with melanoma, lung cancer and renal cancer, immunotherapy has created a group of "super survivors" who can survive for a long time This "long tail effect" is the biggest difference between immunodrugs and targeted drugs Most of the targeted drugs can rapidly shrink the tumor and significantly improve the quality of life of patients in the short term However, it is difficult to get rid of the drug resistance of targeted drugs, so there are few "super survivors", while immunotherapy has produced a number of "super survivors" In fact, many of the patients who were initially treated have survived for more than 10 years "Although it is impossible to solve cancer cells once and for all, today our view on cancer has changed, not to eliminate it, but to transform it." Wu said Because of the magic power of immunotherapy, it has become the main weapon of anti-tumor in the past five years Not only clinicians are using it, but also people's popularization of disease is rapidly increasing "In recent years, our information level has been very developed Many patients and their families know that immunotherapy is a major breakthrough in cancer treatment," Wu said Many patients, early or late, often ask if they can use PD-1 inhibitors The market is very hungry " Wu also revealed that China is currently drafting a new version of the guidelines for the clinical application of anti-tumor drugs to determine the rational application of new anti-cancer drugs Wu Yilong himself is the leader of the drafting group In the future, this guiding principle will be required to be implemented by doctors all over the country, and will be checked As a standard for hospital evaluation and doctor rating, it will play a normative role in China's anti-cancer drugs Can the state pay for three times of mentioning health insurance immunotherapy? Bristol Myers Squibb didn't announce the price of the new drug at the Odyssey meeting, but Zhao Ping said the price would take into account the value of the drug itself, the affordability of Chinese patients and unmet medical needs In China, where social security is the dominant single payer, the biggest response to the medical demands of cancer patients comes from the access of medical insurance Health point noted that at the communication meeting on the same day, Zhao Ping mentioned at least three times the expectation of odiwo entering the medical insurance "For the future, we will actively respond to and participate in various forms of health care negotiations We hope that odivo can enter the negotiation directory as soon as possible and help more patients." Zhao Ping said So far, China has undergone four national health insurance catalog adjustments in 2000, 2004, 2009 and 2017 Especially in 2017, in the process of catalog adjustment, the Ministry of human resources and social security adopted the negotiation access mechanism for some high-value patent drugs with significant curative effect on cancer and other serious diseases, which effectively solved the clinical needs of the majority of patients and had a huge social impact At present, the newly established national medical insurance bureau is also carrying out special negotiations on medical insurance access for exclusive anti-cancer drugs out of some catalogues In April 2017, the Ministry of human resources and social security asked for public opinions and put forward the hope to establish a dynamic adjustment mechanism of medical insurance catalog, gradually integrate with international rules, and realize the refinement and scientization of catalog management On the other hand, it can also encourage the application of new medical technology and innovative drug research and development In response, Zhao Ping told healthpoint, "the dynamic catalog adjustment is a very good measure We hope to start the dynamic adjustment as soon as possible when the new drugs are on the market, so that innovative drugs including odivo can be added to the negotiation catalog of medical insurance." Of course, the choice and adoption of cancer drugs by both medical insurance payers and clinicians are carefully measured by comprehensive factors In fact, from 2014 to 2016, the American Society of Clinical Oncology (ASCO) and the European Society of internal Oncology (ESMO) have proposed a "value framework scoring system" for cancer drug treatment This system not only evaluates the curative effect of anti-tumor treatment, but also combines multi-dimensional factors such as patients' economic ability and medical insurance coverage to focus on the comprehensive value of treatment and strive to provide patients with "optimal treatment" Therefore, Zhao Ping calls for more research on the theory and practice of pharmacoeconomics, and for more choice of clinical tumor drugs to turn to the direction of value medicine Zhao Ping's Qi comes from the clinical effect of immunotherapy According to the clinical trial checkmat-078 registered by odevo, odevo can reduce the risk of death of patients with advanced non-small cell lung cancer by 32% Compared with the control group, it has great advantages in survival, safety, effectiveness, etc The media interview on the listing of BMS in the transformation of odiwo in China is the first time that Zhao Ping has been interviewed by the media four months after she assumed the post of Shi Guibao of new baishimei and served as the general manager of mainland China and Hongkong This is actually the second time Zhao Ping and Shi Guibao have got together In 1993, Zhao Ping, then the obstetrician and gynaecologist of Shanghai No 10 people's Hospital, joined us and China Squibb Now, Zhao Ping still has a good memory of Squibb's marketing and promotion of tumor drug taxol (taxol injection) 21 years later, he returned to Bristol Myers Squibb after training in many multinational pharmaceutical companies, which coincided with the company's listing of China's first immune tumor drug In the eyes of the first female general manager of Bristol Myers Squibb in Chinese history, the intersection of life and career has a wonderful sense of reincarnation Bristol Myers Squibb, a company, has also undergone great changes in the past 20 years Today, Bristol Myers Squibb has completed the divestiture of most non pharmaceutical businesses and transformed into a biopharmaceutical enterprise focusing on specialty drugs At the end of 2014, Bristol Myers Squibb adjusted almost all business units in China, including diabetes business unit and OTC business unit The reason is simple: Bristol Myers Squibb has transformed into a specialty drug biopharmaceutical company in the world As an important strategic development direction, China has also kept pace and started to layout the company's future development Now, Bristol Myers Squibb has completed the transformation of its product line and business model in China, and has become one of the important R & D, production, marketing and innovation centers of Bristol Myers Squibb in the world Since the strategic adjustment to the new generation of Biopharmaceutical Enterprises was made in 2007, Bristol Myers Squibb has begun to focus on the research of innovative drugs in the fields of diseases that are seriously unsatisfied with patients' needs, such as tumor, immune tumor (I-O), immune science, anti fibrosis products, cardiovascular diseases and other fields And the transformation began to show results after suffering In May, the first quarter results released by BMS showed that opdivo alone generated $1.51 billion in revenue, an increase of 34% over the same period last year In the second quarter of July, it was up 36% year on year In China, Bristol Myers Squibb focuses on the local high incidence and unsatisfied treatment fields, focuses on viral hepatitis, immune tumor, cardiovascular disease and other fields, leads the industry development, carries out multiple cooperation, accelerates the introduction of innovative drugs, and helps Chinese patients overcome serious diseases Zhao Ping said frankly that before, many drugs had been listed in foreign countries for many years before they would be tested in China "It's not innovation, it's just clinical trials that validate data In the past decade, many new drugs began to speed up clinical trials in China, which is really considering the needs of Chinese patients " At present, Bristol Myers Squibb has carried out more than 20 I-O clinical studies in China, most of which are phase III clinical studies "I think Bristol Myers Squibb has a long way to go," Zhao said "There are not many companies in China that can have 25 clinical trials of immune tumors." It is undoubtedly the most important thing to popularize the new drugs such as odevo into clinical practice as soon as possible "We will actively cooperate with relevant departments and parties, do a good job in medical insurance access, bidding, hospital admission, drug delivery, etc., and strive to make patients get products as soon as possible and improve drug access." At present, innovative pharmaceutical companies, including MSD, Hengrui, Xinda and so on, are also fast-moving Four companies' tumor immune drugs have entered the priority evaluation channel of the State Drug Administration Of course, China's broad cancer treatment market can accommodate more competitors "In the end, we hope that innovative drugs, including odevo, can enter the national health insurance as soon as possible and benefit more patients." Zhao Ping stressed again.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.